1McClung MR, San Martin J, et al.Opposite bone remodel- ing effects of teriparatide and alendronate in increasing bone mass[J].Arcb Int Meal,2005,165: 1762-1768. 被引量：1
2Widler L, Jaeggi KA, GlattM, et al. Highly potent geminal bisphospnonates. From pamidronate disodium (Aredia) to zoledronicacid (Zometa) [ J ] .J Med Chem, 2002, 45 (17): 3721-3738. 被引量：1
3Van den WT, HuizingMT, Vermorken JB. Bisphosphonates and osteonecrosis of the jaw : cause and effect or a post hoc faffacy [ J]. Ann Oncol, 2006, 17 (8): 1197-1204. 被引量：1
5Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing ep idem- ic [ J ].OralMaxillofac Surg, 2003, 61 (9): 1115-1117. 被引量：1
6Durie BGM, Katz M, Crowley J. Osteonecrosis of the jaw and bisphosphonates[J].N Engl J Med, 2005, 353: 99-102. 被引量：1
7DimopoulosMA, Kastritis E, Anagnostopoulos A, et al. Os- teonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: evidence of increased risk after treatment with zoledronic acid [J].Haematologica, 2006, 91 (7) : 968-971. 被引量：1
8Zervas K,Verrou E, Teleioudis Z, et aL incidence risk fac- tors and management of osteonecrosis of the jaw in pa- tients with multiple myeloma: a single - centre experience in 303 patients[ J].Br J Haematol, 2006, 134 (6): 620-623. 被引量：1
9Sato M, Grasser W.Bisphosphonate action: alendronate lo- calization in rat bone and effects on osteoclast ultrastruc- ture[ J].ClinInvest, 1991,(88): 2095-2105. 被引量：1
10Abu-Id MH, Warnke PH, Gottschalk J, el al. "Bis-phossy jaws"-high and low risk factors for bisphosphonate-in- duced osteonecrosis of the jaw [J]..Craniomaxillofac Surg, 2008,36(2):95-103. 被引量：1
2Fleisch H.Biphosphonates:a new class of drugs in diseases of boneand calcium metabolism[J].Recent Results Cancer Res,1989,116:1-28. 被引量：1
3Lin JH.Bisphosphonates:a review of their farmacokinetic proper-ties[J].Bone,1996,18:75-85. 被引量：1
4Body JJ.Clinical research update zoledronate[J].Cancer,1997,80:1699-1701. 被引量：1
5Sato M,Grasser W.Bisphosphonate action:alendronate localiza-tion in rat bone and effects on osteoclast ultrastructure[J].J ClinInvest,1991,88:2095-2105. 被引量：1
6Rodan GA,Fleisch HA.Bisphosphonates:Mechanisms of action[J].J Clin Invest,1996,97:2692-2696. 被引量：1
7McClung MR,San Martin J,et al.Opposite bone remodelingeffects of teriparatide and alendronate in increasing bone mass[J].Arch Int Med,2005,165:1762-1768. 被引量：1
8Suzuki K,Takeyama S.Current topics in pharmacological researchon bone metabolism:inhibitory effects of bisphosphonates on thedifferentiation and activity of osteoclasts[J].J Pharmacol Sci,2006,100:189-194. 被引量：1
9Rogers MJ,Gordon S.Cellular and molecular mechanisms of actionof bisphosphonates[J].Cancer,2000,88:2961-2978. 被引量：1
10Wood J,Bonjean K.Novel antiangiogenic effects of the bisphospho-nate compound zoledronic acid[J].The J Pharmacol Exp Ther,2002,302:1055-1061. 被引量：1
